U.S. markets close in 5 hours 47 minutes
  • S&P 500

    +13.94 (+0.31%)
  • Dow 30

    +129.11 (+0.36%)
  • Nasdaq

    +9.70 (+0.06%)
  • Russell 2000

    +0.34 (+0.02%)
  • Crude Oil

    -0.82 (-0.99%)
  • Gold

    +8.00 (+0.45%)
  • Silver

    +0.21 (+0.87%)

    +0.0012 (+0.10%)
  • 10-Yr Bond

    +0.0040 (+0.24%)

    +0.0003 (+0.02%)

    -0.0990 (-0.09%)

    +3,672.18 (+5.89%)
  • CMC Crypto 200

    +50.89 (+3.44%)
  • FTSE 100

    -12.62 (-0.17%)
  • Nikkei 225

    +40.03 (+0.14%)

The five-year returns have been massive for Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders despite underlying losses increasing

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are hard to find, but they can generate massive returns over long periods. Just think about the savvy investors who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares for the last five years, while they gained 747%. This just goes to show the value creation that some businesses can achieve. In more good news, the share price has risen 50% in thirty days. We note that Aurinia Pharmaceuticals reported its financial results recently; luckily, you can catch up on the latest revenue and profit numbers in our company report. Anyone who held for that rewarding ride would probably be keen to talk about it.

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

See our latest analysis for Aurinia Pharmaceuticals

Given that Aurinia Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last 5 years Aurinia Pharmaceuticals saw its revenue grow at 95% per year. Even measured against other revenue-focussed companies, that's a good result. Fortunately, the market has not missed this, and has pushed the share price up by 53% per year in that time. It's never too late to start following a top notch stock like Aurinia Pharmaceuticals, since some long term winners go on winning for decades. So we'd recommend you take a closer look at this one, but keep in mind the market seems optimistic.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).


We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

Aurinia Pharmaceuticals shareholders are up 20% for the year. But that was short of the market average. It's probably a good sign that the company has an even better long term track record, having provided shareholders with an annual TSR of 53% over five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. It's always interesting to track share price performance over the longer term. But to understand Aurinia Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 2 warning signs for Aurinia Pharmaceuticals that you should be aware of before investing here.

Aurinia Pharmaceuticals is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.